Integrating routine hemoglobin A1c screening in blood donation: A strategy for early diabetes detection and donor health awareness
Transfusion · 2026-11 · 66 (11) · 2262-2272
DOI: 10.1111/trf.70238 ↗At a glance
Beobachtungsstudie in Transfusion, published online on 2026-06-08. Written by Yaseen Jamal and 12 co-authors. Institution: Department of Pathology, Stanford University School of Medicine, Stanford, California, USA. Major MEDLINE topics: Glycated Hemoglobin, Blood Donation, Blood Donors, Diabetes Mellitus. 21 references. Funded by: Abbott Laboratories.
Topics: Diabetes mellitus
Abstract (original language)
Background
More than 1 in 10 adults worldwide have diabetes, with nearly 50% undiagnosed. Hemoglobin A1c (HbA1c) testing is widely available to identify disease status and blood donation centers can play a pivotal role in public health promotion with routine screening.
Methods
We performed a prospective observational study implementing HbA1c testing at a community blood center over a 1‐year period. Demographic data and history of pre‐diabetes/diabetes status were collected. Donors with abnormally elevated HbA1c without disease history were notified of a new diabetes/pre‐diabetes diagnosis.
Results
Overall, 17.7% of donors had elevated HbA1c levels. Strikingly, 64.9% of abnormal results represented new diagnoses, primarily pre‐diabetes (91.6%). Significant differences in the proportions of new diagnoses were found by donor type (whole blood, platelets) and demographic (age, gender, ethnicity). Donors with abnormal HbA1c values donated significantly more frequently than those with normal HbA1c values. Finally, 17.8% of donors with new diagnoses reported acknowledgement of the new diagnoses on a subsequent donation in the study period.
Conclusions
Incorporating HbA1c testing in blood donation centers is an effective strategy for early diabetes detection, underscored by the substantial proportion of new diagnoses. Further, observed differences across donation types and demographic groups reveal disproportionately underdiagnosed populations for targeted outreach. Moreover, enhanced follow‐up strategies are warranted to improve donor awareness of disease status. Finally, donation behavior changes were observed in those with pre/diabetes, highlighting the feasibility of incorporating screening, though distinct trends in subgroups define key considerations to optimize public health impact.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
- Stanford Blood Center, Palo Alto, California, USA.
- Abbott Laboratories, Abbott Park, Illinois, USA.
ORCID profiles: Yaseen Jamal, Suchitra Pandey
Funding
- Abbott Laboratories
Cite
APA
Jamal, Y., Layon, A., Michelin, L., Mateo, D., Panesa, D., Meceda, P., Bevington, S., Hodghead, K., Bennett, J., Powers, L., Pandey, S., Kieffer, T., & Pham, T. (2026). Integrating routine hemoglobin A1c screening in blood donation: A strategy for early diabetes detection and donor health awareness. Transfusion, 66(11), 2262-2272. https://doi.org/10.1111/trf.70238
Vancouver
Jamal Y, Layon A, Michelin L, Mateo D, Panesa D, Meceda P, et al. Integrating routine hemoglobin A1c screening in blood donation: A strategy for early diabetes detection and donor health awareness. Transfusion. 2026;66(11):2262-2272. doi:10.1111/trf.70238
BibTeX
@article{Jamal2026,
author = {Jamal, Yaseen and Layon, Arlene and Michelin, Leonardo and Mateo, Desireny and Panesa, Deniece and Meceda, Pamela and Bevington, Scott and Hodghead, Kathryn and Bennett, Jenn and Powers, Lee and Pandey, Suchitra and Kieffer, Theodore and Pham, Tho},
title = {Integrating routine hemoglobin A1c screening in blood donation: A strategy for early diabetes detection and donor health awareness},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {11},
pages = {2262--2272},
doi = {10.1111/trf.70238}
}
EUVIMED